Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

262 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prospective evaluation of bone markers, parathormone and 1,25-(OH)₂ vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz.
Focà E, Motta D, Borderi M, Gotti D, Albini L, Calabresi A, Izzo I, Bellagamba R, Narciso P, Sighinolfi L, Clò A, Gibellini D, Quiros-Roldan E, Brianese N, Cesana BM, Re MC, Torti C. Focà E, et al. Among authors: narciso p. BMC Infect Dis. 2012 Feb 14;12:38. doi: 10.1186/1471-2334-12-38. BMC Infect Dis. 2012. PMID: 22333484 Free PMC article. Clinical Trial.
A randomized, pilot trial to evaluate glomerular filtration rate by creatinine or cystatin C in naive HIV-infected patients after tenofovir/emtricitabine in combination with atazanavir/ritonavir or efavirenz.
Albini L, Cesana BM, Motta D, Focà E, Gotti D, Calabresi A, Izzo I, Bellagamba R, Fezza R, Narciso P, Sighinolfi L, Maggi P, Quiros-Roldan E, Manili L, Guaraldi G, Lapadula G, Torti C. Albini L, et al. Among authors: narciso p. J Acquir Immune Defic Syndr. 2012 Jan 1;59(1):18-30. doi: 10.1097/QAI.0b013e31823a6124. J Acquir Immune Defic Syndr. 2012. PMID: 21992924 Clinical Trial.
Increase in standard cholesterol and large HDL particle subclasses in antiretroviral-naïve patients prescribed efavirenz compared to atazanavir/ritonavir.
Gotti D, Cesana BM, Albini L, Calabresi A, Izzo I, Focà E, Motta D, Bellagamba R, Fezza R, Narciso P, Sighinolfi L, Maggi P, Brianese N, Quiros-Roldan E, Guaraldi G, Torti C. Gotti D, et al. Among authors: narciso p. HIV Clin Trials. 2012 Sep-Oct;13(5):245-55. doi: 10.1310/hct1305-245. HIV Clin Trials. 2012. PMID: 23134625
Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort.
Tozzi V, Zaccarelli M, Narciso P, Trotta MP, Ceccherini-Silberstein F, De Longis P, D'Offizi G, Forbici F, D'Arrigo R, Boumis E, Bellagamba R, Bonfigli S, Carvelli C, Antinori A, Perno CF. Tozzi V, et al. Among authors: narciso p. J Infect Dis. 2004 May 1;189(9):1688-95. doi: 10.1086/382960. Epub 2004 Apr 13. J Infect Dis. 2004. PMID: 15116307 Clinical Trial.
Neuroactive antiretroviral drugs do not influence neurocognitive performance in less advanced HIV-infected patients responding to highly active antiretroviral therapy.
Giancola ML, Lorenzini P, Balestra P, Larussa D, Baldini F, Corpolongo A, Narciso P, Bellagamba R, Tozzi V, Antinori A. Giancola ML, et al. Among authors: narciso p. J Acquir Immune Defic Syndr. 2006 Mar;41(3):332-7. doi: 10.1097/01.qai.0000197077.64021.07. J Acquir Immune Defic Syndr. 2006. PMID: 16540934
Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors.
Tozzi V, Balestra P, Bellagamba R, Corpolongo A, Salvatori MF, Visco-Comandini U, Vlassi C, Giulianelli M, Galgani S, Antinori A, Narciso P. Tozzi V, et al. Among authors: narciso p. J Acquir Immune Defic Syndr. 2007 Jun 1;45(2):174-82. doi: 10.1097/QAI.0b013e318042e1ee. J Acquir Immune Defic Syndr. 2007. PMID: 17356465
Randomized clinical trial on efficacy of fixed-dose efavirenz/tenofovir/emtricitabine on alternate days versus continuous treatment.
Bellagamba R, Giancola ML, Tommasi C, Piselli P, Tempestilli M, Angeletti C, Zaccarelli M, Ammassari A, Pinnetti C, Gallo AL, Antinori A, Narciso P, Nicastri E; ATAD Study Group. Bellagamba R, et al. Among authors: narciso p. AIDS. 2019 Mar 1;33(3):493-502. doi: 10.1097/QAD.0000000000002067. AIDS. 2019. PMID: 30702517 Clinical Trial.
Prevalence and Associated Factors of Neurocognitive Impairment in HIV-Positive Patients on Effective Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Treatment.
Giancola ML, Balestra P, Ammassari A, Ricottini M, Lorenzini P, Angeletti C, Bellagamba R, Tommasi C, Tempestilli M, Zaccarelli M, Pinnetti C, Gallo AL, Antinori A, Narciso P, Nicastri E. Giancola ML, et al. Among authors: narciso p. AIDS Res Hum Retroviruses. 2018 Nov;34(11):907-908. doi: 10.1089/AID.2018.0074. Epub 2018 Jul 23. AIDS Res Hum Retroviruses. 2018. PMID: 29929374 No abstract available.
262 results